FibroGen (FGEN) Competitors $0.57 -0.01 (-1.14%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FGEN vs. ELDN, HRTX, ATAI, CMPS, FDMT, LRMR, DSGN, FULC, ACB, and AMLXShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Eledon Pharmaceuticals (ELDN), Heron Therapeutics (HRTX), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), 4D Molecular Therapeutics (FDMT), Larimar Therapeutics (LRMR), Design Therapeutics (DSGN), Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Eledon Pharmaceuticals Heron Therapeutics Atai Life Sciences COMPASS Pathways 4D Molecular Therapeutics Larimar Therapeutics Design Therapeutics Fulcrum Therapeutics Aurora Cannabis Amylyx Pharmaceuticals Eledon Pharmaceuticals (NASDAQ:ELDN) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Does the media favor ELDN or FGEN? In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than FibroGen. MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for FibroGen. FibroGen's average media sentiment score of 0.80 beat Eledon Pharmaceuticals' score of -0.15 indicating that FibroGen is being referred to more favorably in the news media. Company Overall Sentiment Eledon Pharmaceuticals Neutral FibroGen Positive Do insiders and institutionals believe in ELDN or FGEN? 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ELDN or FGEN more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eledon PharmaceuticalsN/A -189.99% -28.17% FibroGen -67.66%N/A -36.17% Which has more volatility and risk, ELDN or FGEN? Eledon Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Which has better earnings and valuation, ELDN or FGEN? Eledon Pharmaceuticals has higher earnings, but lower revenue than FibroGen. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEledon PharmaceuticalsN/AN/A-$116.54M-$2.01-2.00FibroGen$180.02M0.32-$284.23M-$1.23-0.47 Does the MarketBeat Community favor ELDN or FGEN? FibroGen received 317 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Eledon Pharmaceuticals an outperform vote while only 60.14% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformEledon PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% FibroGenOutperform Votes34460.14% Underperform Votes22839.86% Do analysts recommend ELDN or FGEN? Eledon Pharmaceuticals currently has a consensus target price of $16.00, indicating a potential upside of 298.01%. Given Eledon Pharmaceuticals' higher possible upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than FibroGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryEledon Pharmaceuticals beats FibroGen on 9 of the 17 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.72M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.479.9189.4217.36Price / Sales0.32309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book-0.316.055.314.79Net Income-$284.23M$154.90M$122.54M$225.00M7 Day Performance3.23%1.35%1.42%2.37%1 Month Performance43.20%0.41%2.51%4.40%1 Year Performance-24.88%3.08%25.29%20.10% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen2.533 of 5 stars$0.57-1.1%N/A-24.9%$57.72M$180.02M-0.47570Gap DownELDNEledon Pharmaceuticals2.2283 of 5 stars$3.89-3.7%$16.00+311.3%+140.7%$232.39MN/A-1.9410HRTXHeron Therapeutics3.9355 of 5 stars$1.53-1.6%$5.67+271.6%-22.0%$231.95M$137.74M-8.47300Analyst UpgradePositive NewsATAIAtai Life Sciences2.0442 of 5 stars$1.38-8.0%$9.00+552.2%-14.1%$231.57M$331,000.00-1.7080CMPSCOMPASS Pathways3.0413 of 5 stars$3.36-4.8%$33.60+900.0%-56.5%$229.90MN/A-1.53120News CoverageGap UpFDMT4D Molecular Therapeutics3.4735 of 5 stars$4.81-12.9%$38.56+701.6%-73.1%$222.36M$17,000.00-1.69120Analyst ForecastLRMRLarimar Therapeutics1.3882 of 5 stars$3.48-4.9%$20.43+487.0%-22.0%$222.05MN/A-3.0330Gap UpDSGNDesign Therapeutics1.5937 of 5 stars$3.90-13.7%$7.00+79.5%+116.2%$220.82MN/A-4.5940Short Interest ↑News CoverageFULCFulcrum Therapeutics2.0338 of 5 stars$4.09-6.4%$9.33+128.2%-42.8%$220.61M$80.87M-13.19100News CoveragePositive NewsACBAurora Cannabis0.214 of 5 stars$4.01-2.9%N/A-6.4%$220.06M$296.99M-5.281,073Short Interest ↑AMLXAmylyx Pharmaceuticals3.1612 of 5 stars$3.18-9.1%$7.33+130.6%-76.0%$217.98M$196.49M-0.83200 Related Companies and Tools Related Companies Eledon Pharmaceuticals Competitors Heron Therapeutics Competitors Atai Life Sciences Competitors COMPASS Pathways Competitors 4D Molecular Therapeutics Competitors Larimar Therapeutics Competitors Design Therapeutics Competitors Fulcrum Therapeutics Competitors Aurora Cannabis Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FGEN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FGEN Stock Alerts